Journal of Oil Palm Research Vol. 28  March 2016 p.  34-43
DOI: https://doi.org/10.21894/jopr.2016.2801.05

SAFETY ASSESSMENT OF TOCOTRIENOL SUPPLEMENTAT ION IN SUBJECTS WITH METABOL IC SYNDROME: A RANDOMISED CONTROL TRIAL

Author(s): GAN YEE LIN*; LAI OI MING*; CHEW BOON HOW**; YUEN KAH HAY ‡; KALANITHI NESARETNAM‡‡; TENG KIM-TIU‡‡; KANGA RANI SELVADURAY ‡‡; PUVANES WARI MEGANATHAN ‡‡ AND FU JU YEN‡‡

Previous studies have reported that tocotrienols (T3) possess many distinct properties such as antioxidant, cardioprotective, neuroprotective, anti-cancer, anti-inflammatory and anti-angiogenic, which are beneficial for the improvement of human health. However, there is limited data available on the safety assessment of T3 compared to tocopherols (T). A randomised, double-blinded, cross-over and placebo-controlled human clinical trial was conducted to determine the safety and tolerance of T3 supplementation in 31 subjects with metabolic syndrome. The subjects were supplemented with tocotrienol-rich fraction (TRF) 200 mg or placebo capsules twice daily for two weeks followed by a post-intervention visit. Results showed that T3 supplementation had no significant adverse effect on the red blood cell (RBC), white blood cell (WBC) and platelet counts between TRF (5.10 ± 0.78 x 1012 litre-1, 7.35 ± 1.59 x 109 litre-1, 279.45 ± 73.86 x 109 litre-1, respectively) and placebo interventions (5.13 ± 0.76 x 1012 litre-1, 7.25 ± 1.95 x 109 litre-1, 267.45 ± 68.72 x 109 litre-1, respectively). Measures of serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT)) and albumin did not differ between TRF (25.68 ± 10.72 IU litre-1, 38.26 ± 24.74 IU litre-1, 43.61 ± 2.26 g litre-1, respectively) and placebo interventions (27.39 ± 16.44 IU litre-1, 42.23 ± 33.58 IU litre-1, 43.68 ± 2.15 g litre-1, respectively).This study indicated that supplementation with T3 at the dosage of 400 mg per day for 14 days did not induce haematoxicity and hepatotoxicity in subjects with metabolic syndrome.

Keywords: , , ,

Author Information
* Department of Bioprocess Technology, Faculty of Biotechnology and Biomolecular Sciences, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia.

** Department of Family Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, 43400 UPM Serdang, Selangor, Malaysia.

‡ School of Pharmaceuticals, Universiti Sains Malaysia, 11800 Minden, Pulau Pinang, Malaysia.

‡‡ Malaysian Palm Oil Board, 6 Persiaran Institusi, Bandar Baru Bangi, 43000 Kajang, Selangor, Malaysia. E-mail: fujuyen@mpob.gov.my


Cited By

Call For Papers

Article In Press

Search for:


Most cited articles


SIGN UP To JOPR MAILING LIST

Subscribe with us to get the latest information on Palm Oil Research from MPOB today!